Module 1 gave you the receptor subtype framework — the molecular addresses and signal transduction pathways that define adrenergic pharmacology. Module 2 puts that framework to immediate use by introducing the catecholamines: epinephrine, norepinephrine, dopamine, and dobutamine. These four agents are among the most clinically consequential drugs in medicine, used daily in emergency departments, intensive care units, and operating rooms to manage shock, cardiac arrest, anaphylaxis, and heart failure. Their differences in receptor selectivity — which you now have the tools to understand — determine everything about how they behave in patients. Work through these questions with the receptor subtype map from Module 1 in mind. By the end, you should be able to predict the hemodynamic profile of each catecholamine from first principles rather than from memory alone.
1. Epinephrine (adrenaline) is the prototypical endogenous catecholamine with activity at multiple adrenergic receptor subtypes. Which of the following correctly describes epinephrine's receptor profile and the physiological basis for its use as the first-line treatment in anaphylaxis?
A) Epinephrine activates alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors — alpha-1 activation produces vasoconstriction that reverses the distributive hypotension and angioedema of anaphylaxis; beta-2 activation produces bronchodilation that reverses bronchospasm; beta-1 activation increases cardiac output; this broad receptor activity makes epinephrine uniquely suited to simultaneously address the cardiovascular collapse, airway obstruction, and urticaria of anaphylaxis
B) Epinephrine activates only beta-1 and beta-2 adrenergic receptors — beta-1 activation increases heart rate and contractility to maintain cardiac output, and beta-2 activation produces bronchodilation; alpha receptors are not activated at therapeutic anaphylaxis doses because epinephrine has negligible alpha receptor affinity
C) Epinephrine activates alpha-1 receptors exclusively at the doses used in anaphylaxis — producing vasoconstriction that reverses hypotension; beta receptor activation requires much higher doses than those used clinically and does not contribute to the treatment of anaphylaxis
D) Epinephrine is a selective beta-2 agonist at low doses and becomes a non-selective alpha agonist only at supraphysiological doses; in anaphylaxis, the beta-2-mediated bronchodilation is the primary therapeutic effect and the cardiovascular effects are largely unwanted side effects managed with concurrent fluid resuscitation
E) Epinephrine activates all five adrenergic receptor subtypes (alpha-1, alpha-2, beta-1, beta-2, beta-3) with equal affinity — the clinical benefit in anaphylaxis comes primarily from beta-3-mediated detrusor relaxation and adipose lipolysis, which reduce histamine storage in mast cells
ANSWER: A
Rationale:
Epinephrine is a non-selective adrenergic agonist with high affinity for alpha-1, alpha-2, beta-1, and beta-2 receptor subtypes. This broad receptor profile is precisely why it is the irreplaceable first-line treatment for anaphylaxis — no other single agent can simultaneously address all the life-threatening components of the anaphylactic response. Alpha-1 activation on vascular smooth muscle produces vasoconstriction, reversing the distributive hypotension and reducing mucosal edema (including laryngeal angioedema) through reduced capillary leak. Beta-2 activation on bronchial smooth muscle produces bronchodilation, reversing the bronchospasm that can cause fatal airway obstruction. Beta-1 activation increases heart rate and cardiac contractility, maintaining cardiac output against the vasodilated, volume-depleted state. The route of administration in anaphylaxis is intramuscular (vastus lateralis), not intravenous, to avoid the exaggerated cardiovascular effects of IV bolus delivery. Epinephrine's catecholamine structure — a catechol ring with a methylated amine side chain — gives it high potency but short duration (rapidly metabolized by COMT and MAO) and no oral bioavailability.
Option B: Option B incorrectly states that epinephrine has negligible alpha receptor affinity. Epinephrine has potent alpha-1 and alpha-2 agonist activity, and alpha-1-mediated vasoconstriction is a critical component of its efficacy in anaphylaxis.
Option C: Option C incorrectly states that epinephrine activates only alpha-1 receptors at anaphylaxis doses. At intramuscular doses used clinically (0.3–0.5 mg), epinephrine activates both alpha and beta receptors simultaneously — this dual activation is essential to its therapeutic effect.
Option D: Option D incorrectly characterizes epinephrine as a selective beta-2 agonist at low doses. Epinephrine activates both alpha and beta receptors across its clinical dose range; it is not beta-2 selective at any therapeutic dose.
Option E: Option E incorrectly states that epinephrine activates all five receptor subtypes with equal affinity and attributes the anaphylaxis benefit to beta-3 effects. Epinephrine has very low beta-3 affinity, and beta-3-mediated effects play no role in anaphylaxis management.
2. Norepinephrine (NE) differs from epinephrine in its receptor selectivity profile, and this difference has important hemodynamic consequences. Which of the following correctly describes norepinephrine's receptor profile and the expected hemodynamic effect when administered intravenously?
A) Norepinephrine activates beta-1 and beta-2 receptors with high affinity but has negligible alpha receptor activity — producing increased heart rate, increased cardiac contractility, and vasodilation through beta-2-mediated smooth muscle relaxation; the net hemodynamic effect is increased cardiac output with decreased systemic vascular resistance
B) Norepinephrine is a pure alpha-1 agonist with no beta receptor activity — producing intense vasoconstriction and increased systemic vascular resistance with no direct cardiac effects; heart rate may decrease reflexively through the baroreceptor reflex
C) Norepinephrine activates alpha-1, alpha-2, and beta-1 receptors with high affinity but has very low beta-2 affinity — producing potent vasoconstriction (alpha-1), increased cardiac contractility (beta-1), and reflex bradycardia through the baroreceptor response to elevated blood pressure; systemic vascular resistance increases substantially
D) Norepinephrine is pharmacologically identical to epinephrine at all receptor subtypes — the two drugs are interchangeable in clinical practice and differ only in their plasma half-life due to differences in COMT methylation at the N-methyl group
E) Norepinephrine selectively activates alpha-2 receptors, producing presynaptic inhibition of further NE release and central sympatholysis; the net hemodynamic effect is reduction in heart rate and blood pressure similar to clonidine
ANSWER: C
Rationale:
Norepinephrine has high affinity for alpha-1, alpha-2, and beta-1 adrenergic receptors but very low affinity for beta-2 receptors — this receptor profile distinguishes it critically from epinephrine. The dominant cardiovascular effects of intravenous NE are: (1) Potent vasoconstriction through alpha-1 receptor activation on vascular smooth muscle, increasing systemic vascular resistance (SVR) and mean arterial pressure (MAP); (2) Positive inotropy through beta-1 activation, increasing cardiac contractility; (3) Reflex bradycardia — the rise in blood pressure activates arterial baroreceptors, which increase vagal tone to the SA node, slowing heart rate and partially or fully counteracting the direct beta-1 chronotropic effect of NE. The absence of significant beta-2 activity means NE produces little vasodilation in skeletal muscle vasculature and no clinically meaningful bronchodilation. NE is the vasopressor of choice in septic shock per current guidelines (Surviving Sepsis Campaign), where its primary role is to restore vascular tone and MAP.
Option A: Option A incorrectly assigns beta-2 activity and vasodilation to norepinephrine. NE has very low beta-2 affinity; it does not produce clinically significant vasodilation and is not associated with decreased SVR.
Option B: Option B incorrectly states that NE is a pure alpha-1 agonist with no beta activity. NE has significant beta-1 activity producing positive inotropy; it is not devoid of cardiac effects.
Option D: Option D incorrectly states that NE and epinephrine are pharmacologically identical. Their receptor profiles differ importantly — epinephrine has significant beta-2 activity that NE lacks — producing different hemodynamic consequences.
Option E: Option E incorrectly describes NE as selectively activating alpha-2 receptors to produce sympatholysis. NE activates alpha-1 predominantly (producing vasoconstriction) and beta-1 (producing inotropy); it is not a sympatholytic agent.
3. Dopamine is a catecholamine with dose-dependent receptor activation that produces qualitatively different hemodynamic effects at different infusion rates. Which of the following correctly describes the dose-dependent receptor activation profile of dopamine?
A) At all infusion rates, dopamine activates only dopaminergic D1 receptors (dopamine receptor subtype 1) in the renal and mesenteric vasculature, producing vasodilation and increased renal blood flow; at no dose does dopamine activate adrenergic alpha or beta receptors directly
B) Dopamine activates beta-2 receptors at low doses (producing bronchodilation), transitions to alpha-1 receptor activation at intermediate doses (producing vasoconstriction), and activates dopaminergic D1 receptors only at high doses; the adrenergic effects always precede the dopaminergic effects as dose increases
C) At low doses (1–3 mcg/kg/min), dopamine activates dopaminergic D1 receptors in renal and mesenteric vasculature, producing vasodilation and natriuresis; at intermediate doses (3–10 mcg/kg/min), beta-1 receptor activation predominates, increasing heart rate and cardiac contractility; at high doses (>10 mcg/kg/min), alpha-1 receptor activation predominates, producing vasoconstriction and increasing systemic vascular resistance
D) Dopamine produces identical hemodynamic effects at all doses — the concept of dose-dependent receptor activation is a pharmacological oversimplification that does not hold in clinical practice; individual patient variability in dopamine receptor expression eliminates any predictable dose-response relationship
E) At low doses, dopamine activates alpha-1 receptors exclusively, producing vasoconstriction; at high doses, beta-1 receptors are activated, producing tachycardia; dopaminergic D1 receptors are only activated by exogenous dopamine agonists such as fenoldopam, not by dopamine itself
ANSWER: C
Rationale:
Dopamine exhibits a well-characterized dose-dependent receptor activation pattern that is clinically important, though it is recognized that the dose thresholds are approximate and overlap exists between ranges in individual patients. At low doses (approximately 1–3 mcg/kg/min), dopamine preferentially activates dopaminergic D1 receptors in the renal and splanchnic (mesenteric) vasculature, producing vasodilation, increased renal blood flow, and natriuresis (sodium excretion). At intermediate doses (approximately 3–10 mcg/kg/min), beta-1 adrenergic receptor activation becomes prominent, producing positive chronotropy and inotropy — increasing heart rate and cardiac contractility and thereby cardiac output. At high doses (greater than 10 mcg/kg/min), alpha-1 adrenergic receptor activation predominates over dopaminergic and beta effects, producing vasoconstriction and increasing SVR and blood pressure. This dose-response ladder made dopamine a versatile but complex vasopressor; however, clinical trials (including SOAP II) have shown higher rates of arrhythmia with dopamine versus norepinephrine in shock, making NE the preferred first-line vasopressor in current practice.
Option A: Option A incorrectly states that dopamine activates only D1 receptors at all doses. Dopamine activates adrenergic alpha-1 and beta-1 receptors at higher infusion rates — this is the pharmacological basis for its vasopressor and inotropic effects at intermediate and high doses.
Option B: Option B incorrectly reverses the sequence of receptor activation with increasing dose. The correct order is dopaminergic (low dose) → beta-1 adrenergic (intermediate dose) → alpha-1 adrenergic (high dose), not beta-2 → alpha-1 → dopaminergic.
Option D: Option D incorrectly dismisses the dose-dependent receptor activation concept. While individual variability exists, the dose-response pattern for dopamine is pharmacologically established and clinically recognized.
Option E: Option E incorrectly reverses the dose-receptor relationship, placing alpha-1 activation at low doses and beta-1 at high doses, and incorrectly states that D1 receptors are not activated by dopamine itself. Dopamine is the endogenous D1 receptor agonist.
4. Dobutamine is a synthetic catecholamine used primarily in the management of acute decompensated heart failure (ADHF) — a condition in which the failing heart cannot generate sufficient cardiac output to meet the body's metabolic demands. Which of the following correctly describes dobutamine's receptor profile and explains why it is preferred over dopamine for inotropic support in ADHF?
A) Dobutamine is a selective alpha-1 agonist that increases cardiac contractility through Gq-mediated calcium release in cardiomyocytes; it is preferred over dopamine because it produces less vasoconstriction and therefore reduces cardiac afterload without causing tachycardia
B) Dobutamine is a non-selective catecholamine with equal affinity for all adrenergic receptor subtypes; it is preferred over dopamine in ADHF because it has a longer half-life, allowing once-daily dosing rather than continuous infusion
C) Dobutamine is a selective D1 receptor agonist that increases renal blood flow and promotes diuresis, thereby reducing preload in ADHF; it is preferred over dopamine because it avoids the tachycardia associated with dopamine's beta-1 activation at intermediate doses
D) Dobutamine is primarily a beta-1 selective agonist (with some beta-2 activity) that increases cardiac contractility and heart rate through Gs/cAMP/PKA-mediated phosphorylation of myocardial proteins; it also produces mild vasodilation through beta-2 activation, reducing afterload; compared to dopamine at inotropic doses, dobutamine causes less tachycardia and does not activate alpha-1 receptors to cause vasoconstriction — making it better suited for the afterload-sensitive failing heart
E) Dobutamine is a selective alpha-2 agonist that reduces sympathetic outflow to the failing heart, allowing the myocardium to recover from catecholamine-mediated toxicity; it is preferred over dopamine because alpha-2-mediated reduction in NE release protects the myocardium from further adrenergic injury
ANSWER: D
Rationale:
Dobutamine is a synthetic catecholamine with predominantly beta-1 adrenergic receptor selectivity, along with modest beta-2 agonist activity and relatively little alpha-1 activity. Its Gs-coupled beta-1 activation raises cAMP in cardiomyocytes, activating PKA, which phosphorylates key contractile proteins — troponin I (reducing calcium sensitivity and enhancing relaxation), phospholamban (increasing SERCA2a activity and calcium reuptake), and L-type calcium channels (increasing calcium influx during systole) — collectively producing positive inotropy and lusitropy (enhanced relaxation). The mild beta-2-mediated vasodilation reduces systemic vascular resistance, decreasing cardiac afterload — beneficial in the pressure-overloaded failing heart. Compared to dopamine at equivalent inotropic doses (3–10 mcg/kg/min range), dobutamine produces less tachycardia and avoids the alpha-1-mediated vasoconstriction that dopamine can cause at higher doses, which would increase afterload and worsen the already compromised cardiac output. Dobutamine is administered as a continuous IV infusion; its half-life is approximately 2 minutes due to rapid COMT metabolism.
Option A: Option A incorrectly identifies dobutamine as a selective alpha-1 agonist. Dobutamine is primarily a beta-1 agonist; alpha-1 activation is not its mechanism of inotropic action and alpha-1-mediated Gq/calcium signaling is not the pathway for dobutamine's cardiac effects.
Option B: Option B incorrectly describes dobutamine as non-selective and incorrectly states it has a long half-life allowing once-daily dosing. Dobutamine has a half-life of approximately 2 minutes and requires continuous IV infusion.
Option C: Option C incorrectly identifies dobutamine as a D1 receptor agonist. Dobutamine acts on adrenergic receptors, not dopaminergic receptors; its inotropic effect is beta-1 adrenergic, not dopaminergic.
Option E: Option E incorrectly identifies dobutamine as a selective alpha-2 agonist reducing central sympathetic outflow. Dobutamine has no alpha-2 agonist activity and does not reduce sympathetic outflow; it is a direct-acting beta-1/beta-2 adrenergic agonist.
5. All catecholamines share a common structural feature — the catechol ring (a benzene ring with two adjacent hydroxyl groups) — that has critical pharmacokinetic consequences. Which of the following correctly explains why catecholamines cannot be administered orally and have short durations of action?
A) Catecholamines are rapidly inactivated by two enzymatic pathways: catechol-O-methyltransferase (COMT), which methylates the catechol ring hydroxyl groups and inactivates the molecule; and monoamine oxidase (MAO), which oxidatively deaminates the amine side chain; COMT is present in the intestinal wall and liver (explaining first-pass inactivation and lack of oral bioavailability) and in many tissues including the synaptic cleft; MAO is present intraneuronally and in the liver; together these pathways produce plasma half-lives of 1–3 minutes for catecholamines administered intravenously
B) Catecholamines are inactivated exclusively by renal elimination — the catechol ring makes them highly water-soluble and they are filtered at the glomerulus without tubular reabsorption; the short duration of action reflects rapid renal clearance, and oral administration fails because the catechol ring is destroyed by gastric acid before intestinal absorption can occur
C) Catecholamines cannot be given orally because they are large peptide molecules (molecular weight >10,000 Da) that are destroyed by intestinal proteases before reaching the systemic circulation; their short duration of action reflects rapid proteolytic degradation in plasma by catecholamine-specific peptidases
D) The catechol ring renders catecholamines highly lipophilic, causing them to rapidly partition into adipose tissue after IV administration and producing a large volume of distribution; oral administration fails because hepatic first-pass metabolism converts catecholamines to inactive glucuronide conjugates before systemic circulation
E) Catecholamines are inactivated by acetylcholinesterase (AChE) — the same enzyme that degrades acetylcholine in the synaptic cleft; because AChE is ubiquitous at autonomic synapses, catecholamines are rapidly destroyed at the site of release, explaining their short duration; oral administration fails because intestinal AChE inactivates catecholamines before absorption
ANSWER: A
Rationale:
Catecholamines are inactivated by two primary enzymatic pathways operating in parallel. COMT (catechol-O-methyltransferase) methylates one of the hydroxyl groups on the catechol ring, producing O-methylated metabolites (metanephrine from epinephrine, normetanephrine from norepinephrine) — this enzyme is present at high concentrations in the intestinal mucosa, liver, and kidney, as well as extraneuronally at synaptic sites. MAO (monoamine oxidase) oxidatively deaminates the amine side chain; it is located intraneuronally (within sympathetic nerve terminals) and in the liver and intestinal wall. The combined first-pass activity of intestinal COMT and MAO essentially eliminates orally administered catecholamines before they reach the systemic circulation. The same enzymes operating in plasma, liver, and tissues produce plasma half-lives of 1–3 minutes for IV catecholamines — this is why epinephrine, norepinephrine, dopamine, and dobutamine all require continuous IV infusion for sustained effect. Non-catecholamine sympathomimetics (such as albuterol, phenylephrine) lack the catechol ring and are therefore resistant to COMT inactivation, allowing oral administration and longer duration of action.
Option B: Option B incorrectly attributes catecholamine inactivation exclusively to renal elimination. The primary inactivation pathways are enzymatic (COMT and MAO), not renal filtration. Additionally, catecholamines are not destroyed by gastric acid — they are inactivated by enzymes, not acid hydrolysis.
Option C: Option C incorrectly describes catecholamines as large peptide molecules. Catecholamines are small biogenic amines (molecular weight approximately 183–197 Da), not peptides, and are not substrates for intestinal proteases.
Option D: Option D incorrectly describes catecholamines as highly lipophilic. The catechol ring with its two hydroxyl groups makes catecholamines relatively hydrophilic — they have small volumes of distribution and do not partition preferentially into adipose tissue.
Option E: Option E incorrectly attributes catecholamine inactivation to acetylcholinesterase. AChE degrades acetylcholine; it has no activity on catecholamines. Catecholamine inactivation is mediated by COMT and MAO, not AChE.
6. A critical care pharmacist is explaining to medical residents why norepinephrine, rather than epinephrine, is the preferred first-line vasopressor in septic shock. Using receptor profile differences between the two catecholamines, which of the following best explains the pharmacological basis for this preference?
A) Norepinephrine is preferred because it has greater beta-1 activity than epinephrine, producing stronger positive inotropy and higher cardiac output in the hyperdynamic state of septic shock; epinephrine's relatively weak beta-1 activity makes it a less effective vasopressor
B) Norepinephrine is preferred because it is less likely to cause tachyarrhythmias — both NE and epinephrine produce equivalent vasoconstriction through alpha-1 activation, but epinephrine's additional beta-2-mediated vasodilation in skeletal muscle requires higher doses to achieve the same MAP target, and the higher doses needed increase arrhythmia risk
C) Norepinephrine is preferred because it lacks the beta-2 receptor activity of epinephrine — NE's predominant alpha-1 effect produces vasoconstriction that restores MAP without the epinephrine-associated metabolic effects (hyperglycemia, hyperlactatemia) caused by beta-2-mediated hepatic glycogenolysis and muscle glycolysis; epinephrine's beta-2 activity also causes vasodilation in skeletal muscle that partially counteracts the vasopressor effect, requiring higher doses
D) Norepinephrine is preferred because it selectively activates renal dopaminergic D1 receptors in addition to its adrenergic effects, preserving renal blood flow in septic shock; epinephrine has no dopaminergic activity and causes renal vasoconstriction through unopposed alpha-1 activation
E) Norepinephrine is preferred because it crosses the blood-brain barrier and activates central alpha-2 receptors, producing sedation that reduces the metabolic demands of the critically ill patient; epinephrine does not cross the BBB and therefore lacks this centrally beneficial effect
ANSWER: C
Rationale:
The pharmacological basis for preferring norepinephrine over epinephrine in septic shock relates primarily to epinephrine's additional beta-2 receptor activity. Norepinephrine's receptor profile (high alpha-1, beta-1; negligible beta-2) produces a predominantly vasoconstrictive effect that reliably raises MAP — the primary therapeutic goal in distributive shock. Epinephrine, with its additional beta-2 activity, produces beta-2-mediated effects in non-target tissues: beta-2 activation in the liver stimulates glycogenolysis, raising blood glucose (hyperglycemia that can complicate ICU management); beta-2 activation in skeletal muscle increases aerobic and anaerobic glycolysis, raising serum lactate (epinephrine-induced hyperlactatemia) — this lactate elevation can confound the clinical use of lactate as a marker of tissue perfusion in sepsis. Beta-2-mediated vasodilation in skeletal muscle vasculature partially counteracts the vasopressor effect, requiring higher doses of epinephrine to achieve the same MAP target. Clinical trials including CATS (Catecholamines in Septic Shock) have shown that epinephrine is associated with more metabolic derangements than norepinephrine, supporting current Surviving Sepsis Campaign guidelines recommending NE as first-line.
Option A: Option A incorrectly states that NE has greater beta-1 activity than epinephrine. Both agents have comparable beta-1 affinity; the key difference is epinephrine's additional beta-2 activity, not NE's superior beta-1 potency.
Option B: Option B is partially correct in identifying that NE and epinephrine differ in their arrhythmia risk profile, but incorrectly states they produce equivalent vasoconstriction — epinephrine produces additional beta-2-mediated vasodilation in skeletal muscle that partially offsets its alpha-1 vasoconstriction, whereas NE provides more consistent and titratable vasoconstriction; the primary rationale for preferring NE is its more favorable metabolic profile and lower arrhythmia risk, not simply equivalent vasopressor effect with less tachycardia as stated in Option B.
Option D: Option D incorrectly attributes selective D1 dopaminergic activity to norepinephrine. NE does not activate dopaminergic D1 receptors at clinical doses; D1 activation is specific to dopamine and selective D1 agonists like fenoldopam.
Option E: Option E incorrectly states that NE crosses the blood-brain barrier to produce central sedation. NE does not appreciably cross the BBB at clinical doses, and sedation is not a mechanism relevant to vasopressor selection in septic shock.
7. A patient in cardiogenic shock following acute myocardial infarction (MI) has the following hemodynamic profile: blood pressure 78/52 mmHg, heart rate 112 bpm, cardiac index (CI — cardiac output indexed to body surface area) 1.4 L/min/m² (normal >2.2), and systemic vascular resistance (SVR) 1,800 dynes·sec·cm⁻⁵ (elevated). The intensivist selects dobutamine rather than norepinephrine as the primary agent. Which of the following best explains this choice using catecholamine receptor pharmacology?
A) Norepinephrine is avoided because its alpha-1-mediated vasoconstriction would further increase the already elevated SVR, increasing the mechanical work the failing left ventricle must overcome (afterload) — a heart already unable to generate adequate stroke volume cannot compensate for a further increase in outflow resistance; dobutamine's beta-1 inotropy increases contractility and cardiac output, while its mild beta-2-mediated vasodilation reduces SVR (afterload reduction), together improving the hemodynamic profile of cardiogenic shock
B) Dobutamine is selected because it activates alpha-1 receptors more potently than norepinephrine at equivalent doses, producing greater vasoconstriction and faster blood pressure restoration; the higher SVR generated by dobutamine protects coronary perfusion pressure in the post-MI setting
C) Dobutamine is selected because it selectively activates cardiac M2 muscarinic receptors through an off-target effect, reducing heart rate and myocardial oxygen demand while maintaining contractility through a separate calcium-sensitizing mechanism unrelated to beta-1 adrenergic signaling
D) Norepinephrine is avoided because it activates beta-2 receptors in the pulmonary vasculature, causing pulmonary vasoconstriction that worsens right ventricular afterload in cardiogenic shock; dobutamine avoids pulmonary vasoconstriction by selectively activating only systemic beta-1 receptors
E) Dobutamine is selected because it activates dopaminergic D2 receptors in the myocardium, directly stimulating cardiac pacemaker cells and increasing heart rate; the resulting tachycardia increases cardiac output through a rate-dependent mechanism that is more effective than contractility enhancement in cardiogenic shock
ANSWER: A
Rationale:
In cardiogenic shock, the fundamental pathophysiological problem is insufficient cardiac contractility — the damaged left ventricle cannot generate adequate stroke volume and cardiac output. The hemodynamic profile in this patient confirms this: low CI (1.4 L/min/m²), low blood pressure, and compensatory tachycardia (112 bpm). The elevated SVR (1,800 dynes) reflects the compensatory vasoconstriction that the body mounts in response to low cardiac output — this is appropriate physiology but adds to the afterload the failing ventricle must overcome. Adding norepinephrine to a patient whose SVR is already high would further increase afterload through alpha-1-mediated vasoconstriction, potentially worsening cardiac output despite raising blood pressure — the ventricle's inability to generate flow against increasing resistance is a central feature of cardiogenic shock. Dobutamine addresses the primary problem (inadequate contractility) through beta-1-mediated inotropy, while its modest beta-2-mediated vasodilation reduces SVR (reduces afterload), together increasing CI. The goal in cardiogenic shock is to restore cardiac output and tissue perfusion — not simply to raise blood pressure through vasoconstriction.
Option B: Option B incorrectly states that dobutamine has more potent alpha-1 activity than norepinephrine. Dobutamine has relatively little alpha-1 activity; norepinephrine is the more potent alpha-1 agonist. This
Option C: Option C describes a fictitious mechanism — dobutamine does not activate cardiac muscarinic M2 receptors and has no calcium-sensitizing mechanism independent of beta-1 adrenergic signaling.
Option D: Option D incorrectly attributes pulmonary vasoconstriction to norepinephrine's beta-2 activation. Beta-2 activation produces vasodilation (not vasoconstriction) in pulmonary and systemic vasculature. Pulmonary vasoconstriction could result from alpha-1 activation, but this is not the primary reason for choosing dobutamine in this scenario.
Option E: Option E incorrectly attributes dobutamine's mechanism to dopaminergic D2 receptor activation. Dobutamine acts on adrenergic beta-1 (and beta-2) receptors, not dopaminergic receptors, and its benefit in cardiogenic shock comes from improved contractility and cardiac output, not rate-dependent mechanisms.
8. Epinephrine is administered intravenously at two different doses in a pharmacology experiment: a low dose (0.1 mcg/kg/min) and a high dose (1.0 mcg/kg/min). Blood pressure, heart rate, and systemic vascular resistance (SVR) are measured at each dose. Which of the following best predicts the hemodynamic differences between low-dose and high-dose epinephrine, based on receptor pharmacology?
A) Low-dose and high-dose epinephrine produce identical hemodynamic effects — epinephrine activates all adrenergic receptor subtypes equally at all doses and dose-dependent differences in hemodynamic response reflect only pharmacokinetic changes in plasma concentration without any change in receptor activation pattern
B) Low-dose epinephrine produces predominantly beta-2-mediated vasodilation in skeletal muscle vasculature, potentially reducing SVR and diastolic blood pressure while increasing heart rate and contractility (beta-1); high-dose epinephrine produces alpha-1-mediated vasoconstriction that overcomes the beta-2 vasodilation, increasing SVR, raising diastolic blood pressure, and producing a further rise in heart rate and systolic pressure
C) Low-dose epinephrine selectively activates alpha-1 receptors, producing vasoconstriction and hypertension; as dose increases to high levels, alpha-1 receptors are saturated and beta-2 receptors become activated, producing vasodilation that reduces blood pressure — explaining why high-dose epinephrine causes lower blood pressure than low-dose
D) At both low and high doses, epinephrine produces identical receptor activation but the physiological responses differ because baroreceptor reflex sensitivity decreases at higher catecholamine concentrations, allowing high-dose epinephrine to produce greater tachycardia without reflex compensation
E) Low-dose epinephrine activates only beta-3 receptors in adipose tissue, producing lipolysis without cardiovascular effects; cardiovascular effects only emerge at high doses when beta-1 and alpha-1 receptors are recruited — explaining why low-dose epinephrine is safe in patients with cardiac arrhythmias
ANSWER: B
Rationale:
Epinephrine exhibits dose-dependent receptor activation that is well-characterized experimentally and clinically. At low infusion rates, the beta-adrenergic effects predominate: beta-1 activation increases heart rate and contractility, and beta-2 activation produces vasodilation in skeletal muscle vasculature — this can actually decrease diastolic blood pressure and SVR while increasing systolic blood pressure and pulse pressure (a widened pulse pressure is a characteristic sign of low-dose epinephrine). At higher doses, alpha-1 adrenergic receptor activation becomes prominent and overcomes the beta-2-mediated vasodilation — SVR rises, diastolic blood pressure increases, and the overall hemodynamic picture shifts from a predominantly beta-driven, vasodilatory pattern to a predominantly alpha-driven vasoconstrictive pattern. This dose-dependent shift in the alpha-to-beta ratio is why epinephrine at low doses can produce a different hemodynamic profile than epinephrine at high doses — a concept that also underlies the use of low-dose epinephrine in some bradycardia protocols versus high-dose in cardiac arrest.
Option A: Option A incorrectly states that epinephrine produces identical effects at all doses. The dose-dependent shift from beta-predominant to alpha-predominant effects is a well-established pharmacological phenomenon.
Option C: Option C reverses the sequence — low-dose epinephrine does not selectively activate alpha-1 first; beta effects predominate at lower doses and alpha-1 vasoconstriction becomes dominant at higher doses. This
Option D: Option D incorrectly attributes the dose-dependent hemodynamic differences to changes in baroreceptor sensitivity rather than to changes in receptor activation patterns. Baroreceptor reflex sensitivity does not decrease at higher catecholamine concentrations in the clinically relevant range.
Option E: Option E incorrectly states that low-dose epinephrine selectively activates only beta-3 receptors. Epinephrine activates beta-1 and alpha-1 receptors at low doses with cardiovascular consequences; beta-3 selectivity at low doses is not a feature of epinephrine pharmacology.
9. A pharmacology student is constructing a receptor profile comparison table for the four major catecholamines. Which of the following correctly summarizes the receptor selectivity profile that distinguishes dobutamine from dopamine at intermediate infusion rates (3–10 mcg/kg/min for dopamine)?
A) At intermediate doses, dopamine and dobutamine have identical receptor profiles — both are selective beta-1 agonists with no alpha or dopaminergic activity; they differ only in their plasma half-lives due to different susceptibility to COMT metabolism
B) Dopamine at intermediate doses activates beta-1 receptors (increasing heart rate and contractility) and begins to activate alpha-1 receptors (increasing vasoconstriction); dobutamine is a selective beta-1 agonist with additional beta-2 activity and no significant dopaminergic or alpha-1 activity — the key clinical distinction is that dopamine causes more vasoconstriction and tachycardia than dobutamine at equivalent inotropic doses
C) Dopamine at intermediate doses is a selective D2 receptor agonist producing renal vasodilation; dobutamine at equivalent doses is a selective alpha-2 agonist reducing central sympathetic outflow; neither drug activates beta-1 receptors at intermediate doses — beta-1 activation only occurs at the highest infusion rates for both agents
D) Dobutamine has greater D1 dopaminergic activity than dopamine at intermediate doses, explaining its superior renal protective effect in cardiogenic shock; dopamine at intermediate doses is a pure beta-2 agonist producing bronchodilation as its primary effect
E) Dopamine at intermediate doses activates D1 receptors producing renal vasodilation, beta-1 receptors producing inotropy, and some alpha-1 receptors producing vasoconstriction; dobutamine activates beta-1 receptors producing inotropy and beta-2 receptors producing mild vasodilation, with no dopaminergic or significant alpha-1 activity — dobutamine therefore produces less tachycardia and less vasoconstriction than dopamine at equivalent inotropic doses, making it more suitable for afterload-sensitive patients
ANSWER: E
Rationale:
This comparison question highlights the key receptor profile differences between dopamine (at intermediate doses) and dobutamine that have direct clinical implications. Dopamine at intermediate infusion rates (3–10 mcg/kg/min) transitions from predominantly D1-mediated renal vasodilation (low dose range) into beta-1-mediated inotropy and chronotropy, with emerging alpha-1-mediated vasoconstriction as the rate approaches the higher end of this range. Dopamine therefore produces a more complex and variable hemodynamic profile — increased contractility combined with vasoconstriction and often significant tachycardia. Dobutamine, by contrast, is primarily a beta-1 agonist with additional beta-2 agonist activity and minimal alpha-1 and no dopaminergic activity — it produces positive inotropy (beta-1) with mild afterload reduction (beta-2 vasodilation) and less tachycardia than dopamine. For a patient with cardiogenic shock and elevated SVR (afterload), dobutamine's profile (inotropy + afterload reduction) is more favorable than dopamine's (inotropy + vasoconstriction). The SOAP II trial demonstrated that dopamine was associated with more arrhythmias than NE in shock, further contributing to its declining use as a first-line vasopressor/inotrope.
Option A: Option A incorrectly states that dopamine and dobutamine have identical receptor profiles at intermediate doses. Their receptor profiles differ importantly — dopamine has dopaminergic and emerging alpha-1 activity that dobutamine lacks.
Option B: Option B correctly identifies that intermediate-dose dopamine activates beta-1 and begins to activate alpha-1 receptors, and that dobutamine has beta-1 and beta-2 activity, but incorrectly concludes that dopamine is preferred in cardiogenic shock with hypotension; the SOAP II trial demonstrated that dopamine was associated with significantly more arrhythmias than norepinephrine in shock states, and current evidence favors norepinephrine plus dobutamine over dopamine in cardiogenic shock with vasodilatory physiology; Option B also omits the clinically important limitation of dopamine's unpredictable dose-response relationship.
Option C: Option C incorrectly describes dopamine as a D2 agonist at intermediate doses (D1 is the relevant renal dopaminergic receptor) and incorrectly describes dobutamine as an alpha-2 agonist. Neither description is accurate.
Option D: Option D incorrectly states that dobutamine has greater D1 dopaminergic activity than dopamine. Dobutamine has no clinically relevant dopaminergic activity; dopamine is the D1 agonist. Additionally, dopamine at intermediate doses is not a pure beta-2 agonist.
10. A 45-year-old man is brought to the emergency department (ED) in cardiac arrest. After 8 minutes of CPR without return of spontaneous circulation (ROSC), the team administers epinephrine 1 mg IV push per ACLS (Advanced Cardiovascular Life Support) protocol. A student asks the attending physician: "Why epinephrine specifically? What does it do in cardiac arrest that makes it the drug of choice?" Which of the following best explains the pharmacological rationale for epinephrine in cardiac arrest?
A) Epinephrine is used in cardiac arrest because its beta-2 receptor activation produces bronchodilation, keeping the airway patent during CPR; its cardiovascular effects are secondary and alpha receptor activation is actually undesirable because vasoconstriction reduces coronary blood flow
B) Epinephrine is used because it is the only catecholamine that crosses the blood-brain barrier, stimulating central respiratory and vasomotor centers to restore spontaneous breathing and vasomotor tone — its peripheral receptor effects are not the primary mechanism of benefit in cardiac arrest
C) Epinephrine is used in cardiac arrest primarily for its alpha-1-mediated peripheral vasoconstriction — by increasing systemic vascular resistance during CPR compressions, epinephrine raises aortic diastolic pressure, which is the primary determinant of coronary perfusion pressure during CPR; increased coronary perfusion pressure delivers more oxygenated blood to the ischemic myocardium, improving the likelihood of defibrillation and ROSC; the beta-1 effects (increased contractility and automaticity) may also contribute but are secondary to the vasopressor effect
D) Epinephrine is used because it selectively activates cardiac beta-3 receptors, which are upregulated during ischemia and mediate a unique cardioprotective signal transduction cascade that reduces apoptosis in ischemic cardiomyocytes; no other catecholamine has equivalent beta-3 cardioprotective activity
E) Epinephrine is used because it inhibits acetylcholinesterase (AChE), increasing synaptic acetylcholine at the SA node and restoring parasympathetic pacemaker function; the resulting increase in SA nodal automaticity restores a perfusing rhythm more effectively than direct adrenergic stimulation
ANSWER: C
Rationale:
The primary pharmacological rationale for epinephrine in cardiac arrest is its alpha-1-mediated vasoconstriction. During CPR, cardiac compressions generate a forward blood flow that is far below normal physiological cardiac output — typically 25–30% of normal. To deliver this limited flow preferentially to the coronary arteries (which perfuse during diastole, when aortic pressure is highest), it is essential to raise aortic diastolic pressure. Epinephrine's alpha-1-mediated peripheral vasoconstriction increases systemic vascular resistance during compressions, raising aortic diastolic pressure and thereby increasing coronary perfusion pressure (CPP = aortic diastolic pressure − right atrial diastolic pressure). Studies have demonstrated that CPP during CPR is one of the strongest predictors of ROSC. The beta-1 effects of epinephrine (increased automaticity, improved contractility when rhythm is restored) contribute to the likelihood of achieving and sustaining ROSC but are secondary to the vasopressor mechanism. Epinephrine is the only vasopressor with Level I evidence in ACLS for improving ROSC rates, though its effect on long-term neurological outcomes remains the subject of ongoing investigation (including the PARAMEDIC2 trial).
Option A: Option A incorrectly attributes the primary mechanism of benefit in cardiac arrest to beta-2-mediated bronchodilation and incorrectly states that alpha-1 vasoconstriction is undesirable. Alpha-1 vasoconstriction is the primary mechanism of benefit; it increases coronary perfusion pressure, not reduces coronary blood flow.
Option B: Option B incorrectly states that epinephrine crosses the blood-brain barrier and works centrally to restore vasomotor function. Epinephrine does not appreciably cross the BBB; its cardiac arrest benefit is peripheral through alpha-1-mediated vasoconstriction.
Option D: Option D incorrectly attributes epinephrine's cardiac arrest benefit to beta-3 receptor cardioprotection. Beta-3 receptors are not established mediators of epinephrine's ACLS mechanism of action.
Option E: Option E incorrectly attributes epinephrine's mechanism to AChE inhibition. Epinephrine does not inhibit AChE; it is an adrenergic agonist. AChE inhibitors (neostigmine, physostigmine) have the opposite autonomic effect from epinephrine.
11. A 68-year-old woman with ischemic cardiomyopathy (left ventricular ejection fraction 25%) is admitted with acute decompensated heart failure and cardiogenic shock. Her blood pressure is 82/54 mmHg, heart rate is 108 bpm, and she is cool and mottled peripherally. The intensivist starts dobutamine but notes that despite improvement in cardiac output, her blood pressure remains inadequate at 86/58 mmHg. A second vasopressor is added. Which combination best reflects rational catecholamine pharmacology for this scenario?
A) Add epinephrine at high dose — its combined alpha-1 and beta-1 activity will increase both SVR and contractility simultaneously, eliminating the need for dobutamine; stopping dobutamine reduces the risk of tachyarrhythmias from two catecholamines
B) Add dopamine at low dose (1–3 mcg/kg/min) for its D1-mediated renal vasodilation — the renal protective effect of low-dose dopamine will improve urine output and reduce the risk of acute kidney injury without affecting blood pressure or heart rate
C) Add vasopressin — a non-catecholamine vasopressor that acts on V1 receptors in vascular smooth muscle to produce vasoconstriction independent of adrenergic receptors; combining dobutamine (inotropy) with vasopressin (vasoconstriction) addresses both the contractility deficit and the inadequate vascular tone without adding further catecholamine-mediated tachycardia or arrhythmia risk
D) Add norepinephrine — its alpha-1-mediated vasoconstriction will raise SVR and MAP without the beta-2-mediated vasodilation that epinephrine would introduce; combining dobutamine (beta-1 inotropy + mild beta-2 vasodilation) with norepinephrine (alpha-1 vasoconstriction) creates a pharmacologically rational combination that addresses both low contractility and low vascular tone
E) Add phenylephrine — a pure alpha-1 agonist that increases SVR without any beta-1 cardiac stimulation; the absence of chronotropic effect is beneficial because it avoids worsening the already elevated heart rate; phenylephrine is the preferred vasopressor addition in all cardiogenic shock patients requiring blood pressure support beyond dobutamine
ANSWER: D
Rationale:
This question requires integrating catecholamine receptor pharmacology with the pathophysiology of cardiogenic shock to select a rational combination vasopressor/inotrope strategy. The patient has two concurrent problems: (1) inadequate cardiac contractility (cardiomyopathy, EF 25%) — addressed by dobutamine's beta-1 inotropy; (2) inadequate vascular tone — dobutamine's mild beta-2 vasodilation may actually be modestly reducing SVR, and additional vasopressor support is needed to raise MAP to a perfusion-adequate level. Adding norepinephrine is pharmacologically rational because its dominant alpha-1 vasoconstriction raises SVR and MAP without introducing significant additional beta-2-mediated vasodilation (which epinephrine would add) and without further increasing the metabolic derangements of sepsis-like physiology. Vasopressin (Option C) is also a reasonable consideration and is used clinically in this context, but among the options presented, norepinephrine most directly addresses the pharmacological rationale using the catecholamine receptor framework established in this module. Phenylephrine (Option E) carries risk in cardiogenic shock — pure alpha-1 vasoconstriction increases afterload without any inotropic support, which can worsen cardiac output in an afterload-sensitive failing ventricle.
Option A: Option A incorrectly proposes stopping dobutamine and replacing it with high-dose epinephrine. High-dose epinephrine would increase metabolic demands, produce significant tachycardia and arrhythmia risk, and the alpha-1 vasoconstriction would increase afterload on the failing ventricle — a pharmacologically inappropriate combination in cardiogenic shock.
Option B: Option B incorrectly proposes low-dose dopamine for renal protection. Multiple randomized trials have demonstrated that low-dose ("renal dose") dopamine does not protect against acute kidney injury and is not recommended for this purpose in current guidelines.
Option C: Option C describes a clinically reasonable approach (dobutamine + vasopressin) but vasopressin acts through V1 receptors, which is beyond the scope of this catecholamine module. Among the catecholamine-based
Option E: Option E incorrectly recommends phenylephrine as the preferred vasopressor addition in cardiogenic shock. Pure alpha-1 vasoconstriction increases afterload without inotropy, risking further depression of cardiac output in the afterload-sensitive failing ventricle.
12. Having completed the catecholamine section of Module 2, a student reflects on why understanding receptor pharmacology matters for clinical practice: "All of these drugs increase blood pressure — why does it matter which one we use?" Which of the following best answers this question and captures the key clinical pharmacology principle of Module 2?
A) It does not matter which catecholamine is used to raise blood pressure — all agents that increase MAP achieve the equivalent clinical outcome; the choice between epinephrine, norepinephrine, dopamine, and dobutamine is based entirely on cost and availability rather than receptor pharmacology
B) The choice of catecholamine matters because each agent's distinct receptor profile produces a qualitatively different hemodynamic response — raising MAP through alpha-1-mediated vasoconstriction (norepinephrine) is mechanistically different from raising MAP through beta-1-mediated inotropy (dobutamine) or through a combination of both (epinephrine); the underlying pathophysiology determines which hemodynamic mechanism is appropriate: distributive shock (sepsis) needs vasoconstriction; cardiogenic shock needs inotropy ± afterload reduction; anaphylaxis needs both simultaneously; choosing the wrong mechanism can worsen the underlying problem even while temporarily raising MAP
C) The choice of catecholamine matters only in patients with known adrenergic receptor polymorphisms — in genetically normal patients, all catecholamines produce equivalent clinical outcomes because receptor expression is standardized; pharmacogenomic testing should guide catecholamine selection before initiating vasopressor therapy
D) The choice of catecholamine matters because different agents have different oral bioavailability — epinephrine and norepinephrine can be given orally in stable patients while dopamine and dobutamine require IV infusion; oral agents are preferred in non-critically ill patients to reduce central venous access complications
E) The choice matters only in pediatric patients — adult adrenergic receptors are uniformly distributed and equivalently responsive to all catecholamines; pediatric receptors have age-dependent expression patterns that require catecholamine-specific dosing protocols
ANSWER: B
Rationale:
This integrative closing question captures the central clinical pharmacology lesson of Module 2: receptor pharmacology is not academic — it directly determines which drug is right for which patient in which pathophysiological state. Blood pressure is an output variable, but the mechanism by which it is raised matters enormously. Raising MAP by increasing SVR (alpha-1-mediated vasoconstriction with norepinephrine) is appropriate in distributive shock where vascular tone is the primary deficit — but would be harmful in cardiogenic shock where increasing afterload on a failing ventricle worsens cardiac output despite raising MAP. Raising MAP through inotropy (beta-1 with dobutamine) is appropriate in cardiogenic shock where contractility is the primary deficit — but dobutamine's mild vasodilation would be inadequate and potentially harmful in septic shock where the primary problem is profound vasodilation. Epinephrine's broad receptor profile makes it uniquely appropriate for anaphylaxis, where simultaneous alpha-1 vasoconstriction, beta-2 bronchodilation, and beta-1 cardiac support are all needed. The receptor pharmacology framework developed in Modules 1 and 2 allows the clinician to reason from pathophysiology to drug selection — which is precisely the skill this module set out to build.
Option A: Option A incorrectly dismisses the importance of receptor pharmacology in catecholamine selection. The receptor profile of each agent directly determines its hemodynamic mechanism, and using the wrong mechanism for the underlying pathophysiology can cause harm even while temporarily improving MAP.
Option C: Option C incorrectly attributes catecholamine selection to pharmacogenomic testing in genetically normal patients. While receptor polymorphisms exist and can affect response, catecholamine selection in clinical practice is guided by receptor pharmacology and pathophysiology, not routine genotyping.
Option D: Option D incorrectly states that epinephrine and norepinephrine can be given orally. All four catecholamines — epinephrine, norepinephrine, dopamine, and dobutamine — cannot be administered orally due to first-pass inactivation by intestinal COMT and MAO, as covered in Question 5 of this module.
Option E: Option E incorrectly limits the importance of catecholamine receptor pharmacology to pediatric patients. Adult adrenergic receptor distribution is not uniform or equivalent across all agents — the receptor pharmacology principles established in this module apply across all age groups.
BEFORE YOU MOVE ON
The four catecholamines covered in this module — epinephrine, norepinephrine, dopamine, and dobutamine — represent the backbone of vasopressor and inotrope therapy in critical care. The framework to carry forward is simple but powerful: know each drug's receptor profile, derive its hemodynamic consequences from first principles, and match those consequences to the underlying pathophysiology. Epinephrine's broad alpha and beta activation makes it the drug for anaphylaxis and cardiac arrest. Norepinephrine's alpha-dominant profile makes it the vasopressor for septic shock. Dobutamine's beta-1 selectivity with mild beta-2 vasodilation makes it the inotrope for cardiogenic shock with elevated SVR. Dopamine's dose-dependent receptor ladder makes it complex and increasingly replaced by more predictable agents in modern practice. Module 3 introduces the non-catecholamine direct-acting agonists — drugs that exploit the same receptor framework but with modified structures that confer oral bioavailability, longer duration, and greater receptor selectivity.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.